Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALM-2: BLU-5937 in Refractory Chronic Cough
jRCT2031230611Phase 3Active, not recruiting
- Sponsor
- BELLUS Health Inc.
- Start
- Feb 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in refractory chronic cough (RCC) and chronic idiopathic cough (CIC) comparing BLU-5937 with Placebo (2 arms). Primary endpoint: 24-hour cough frequency at Week 24. Started Feb 2024; status: active, not recruiting.
02
Drugs
camlipixant
03
Conditions
refractory chronic cough (RCC)chronic idiopathic cough (CIC)
Beyond the preview
Go deeper on jRCT2031230611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230611.